We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+29.97%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$752M
AUM Growth
+$105M
Cap. Flow
-$17.7M
Cap. Flow %
-2.36%
Top 10 Hldgs %
46.3%
Holding
87
New
16
Increased
20
Reduced
11
Closed
7

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$16.7M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$16M
3
DVAX
Dynavax Technologies
DVAX
+$10.9M
4
NVRO
NEVRO CORP.
NVRO
+$10.2M
5
CHRS icon
Coherus Oncology
CHRS
+$8.85M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$39.5M
2
BMY icon
Bristol-Myers Squibb
BMY
+$29.6M
3
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$28.1M
4
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$27.1M
5
CMRX
Chimerix, Inc.
CMRX
+$8.65M

Sector Composition

Rank Sector Weight
1 Healthcare 73.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
1
Alkermes
ALKS
$8.11B
$45M 5.99%
700,000
– –
HRTX icon
2
Heron Therapeutics
HRTX
$93.4M
$44.9M 5.97%
1,440,000
+170,000
+13% +$3.2M
RCPT
3
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
$41.8M 5.56%
220,000
-170,312
-44% -$28.1M
ALDR
4
DELISTED
Alder Biopharmaceuticals
ALDR
$40.1M 5.33%
757,475
+440,000
+139% +$16M
DYAX
5
DELISTED
DYAX CORPORATION
DYAX
$37.1M 4.93%
1,400,000
+261,100
+23% +$6.92M
NBIX icon
6
Neurocrine Biosciences
NBIX
$18.2B
$34.3M 4.56%
718,900
– –
SRNE
7
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$34.3M 4.56%
1,945,334
+292,422
+18% +$3.76M
EGRX
8
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$24.3M 3.23%
300,000
-416,500
-58% -$27.1M
ARDX icon
9
Ardelyx
ARDX
$1.24B
$23.7M 3.14%
1,481,075
+467,290
+46% +$5.89M
PTLA
10
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$22.8M 3.03%
500,000
-74,500
-13% -$3M
NVAX icon
11
Novavax
NVAX
$1.21B
$17.8M 2.37%
80,000
+18,085
+29% +$3.18M
TSRO
12
DELISTED
TESARO, Inc.
TSRO
$17.1M 2.28%
291,250
+100,000
+52% +$5.74M
ALNY icon
13
Alnylam Pharmaceuticals
ALNY
$38.3B
$16.8M 2.23%
+140,000
New +$16.7M
QTNT
14
DELISTED
Quotient Limited Ordinary Shares
QTNT
$16.6M 2.2%
27,978
– –
CHRS icon
15
Coherus Oncology
CHRS
$217M
$16.4M 2.19%
569,130
+350,000
+160% +$8.85M
ADXS
16
DELISTED
Advaxis Inc
ADXS
$16.3M 2.16%
53,333
-11,692
-18% -$3.69M
AGEN
17
Agenus
AGEN
$276M
$13.5M 1.79%
79,431
+7,642
+11% +$1.08M
CBPO
18
DELISTED
China Biologic Products Holdings, Inc.
CBPO
$12.8M 1.71%
111,500
+35,000
+46% +$3.68M
DXCM icon
19
DexCom
DXCM
$29B
$12.2M 1.63%
612,000
– –
PFNX
20
DELISTED
Pfenex Inc.
PFNX
$12.1M 1.61%
624,900
+150,000
+32% +$2.51M
DVAX
21
DELISTED
Dynavax Technologies
DVAX
$11.7M 1.56%
+500,000
New +$10.9M
NVRO
22
DELISTED
NEVRO CORP.
NVRO
$11.2M 1.49%
208,500
+200,000
+2,353% +$10.2M
RARE icon
23
Ultragenyx Pharmaceutical
RARE
$2.46B
$10.4M 1.39%
102,000
– –
BCRX icon
24
BioCryst Pharmaceuticals
BCRX
$2.42B
$10.2M 1.35%
680,000
– –
SCTL
25
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$10.1M 1.34%
869,700
+138,364
+19% +$1.29M
1
2 3 4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $1.98B AUM 19.17% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return

Cormorant Asset Management's Q2 2015 Portfolio in Review

As of Q2 2015, Cormorant Asset Management held 87 positions worth $752M, up 16% from $647M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Cormorant Asset Management's Q2 2015 filing shows 16 new, 20 increased, 11 reduced and 7 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 140,000 shares worth $16.8M. The largest sale was Puma Biotechnology, an estimated $39.5M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 73% a quarter earlier.

  • Cormorant Asset Management's largest Q2 2015 buy was Alnylam Pharmaceuticals: 140,000 shares worth $16.8M.
  • Cormorant Asset Management added most to Alder Biopharmaceuticals in Q2 2015, an estimated $16M increase.
  • Cormorant Asset Management's biggest Q2 2015 reduction was RECEPTOS INC COM STK (DE), cutting an estimated $28.1M.
  • Cormorant Asset Management fully exited Puma Biotechnology in Q2 2015, selling an estimated $39.5M.
  • Cormorant Asset Management's ten largest holdings make up 46% of its $752M portfolio in Q2 2015.
  • Cormorant Asset Management opened 16 new positions and closed 7 in Q2 2015.
  • Cormorant Asset Management's portfolio value rose 16% quarter-over-quarter to $752M.

Based on Cormorant Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.